Adjuvant therapy of pemphigus.
The effectiveness of adjuvant therapy of pemphigus was evaluated by comparing the results of studies of pemphigus treated with corticosteroids and adjuvant as opposed to corticosteroids only. There has been a steady and striking improvement in the prognosis of pemphigus during the past three decades. However, factors other than the use of adjuvant therapy appear to be responsible, since the survival and incidence of remissions in patients treated with adjuvants was only slightly better than that of patients treated with corticosteroids alone. The variable course of pemphigus and the lack of stratification makes it difficult to judge whether these slight differences have any relevance. A suggested protocol to treat pemphigus is presented.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000906:Antibodies / Q000032:analysis; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D002452:Cell Count; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010392:Pemphigus / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D010956:Plasmapheresis; D010976:Platelet Count; D011379:Prognosis
D000305:Adrenal Cortex Hormones; D000906:Antibodies; D007166:Immunosuppressive Agents; D006046:Gold; D003520:Cyclophosphamide; D003622:Dapsone; D001379:Azathioprine